IL240787B - Mimetics of apoflavon and their uses - Google Patents

Mimetics of apoflavon and their uses

Info

Publication number
IL240787B
IL240787B IL240787A IL24078715A IL240787B IL 240787 B IL240787 B IL 240787B IL 240787 A IL240787 A IL 240787A IL 24078715 A IL24078715 A IL 24078715A IL 240787 B IL240787 B IL 240787B
Authority
IL
Israel
Prior art keywords
apolipoprotein mimetics
apolipoprotein
mimetics
Prior art date
Application number
IL240787A
Other languages
English (en)
Hebrew (he)
Other versions
IL240787A0 (en
Original Assignee
Uab Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Res Found filed Critical Uab Res Found
Publication of IL240787A0 publication Critical patent/IL240787A0/en
Publication of IL240787B publication Critical patent/IL240787B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL240787A 2013-03-14 2015-08-24 Mimetics of apoflavon and their uses IL240787B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782956P 2013-03-14 2013-03-14
US201361834992P 2013-06-14 2013-06-14
PCT/US2014/027719 WO2014152776A1 (en) 2013-03-14 2014-03-14 Apolipoprotein mimetics and uses thereof

Publications (2)

Publication Number Publication Date
IL240787A0 IL240787A0 (en) 2015-10-29
IL240787B true IL240787B (en) 2019-07-31

Family

ID=51581312

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240787A IL240787B (en) 2013-03-14 2015-08-24 Mimetics of apoflavon and their uses

Country Status (12)

Country Link
US (1) US20160002315A1 (https=)
EP (1) EP2996706B1 (https=)
JP (2) JP6570511B2 (https=)
AU (2) AU2014239186B2 (https=)
BR (1) BR112015022624A2 (https=)
CA (1) CA2903869A1 (https=)
DK (1) DK2996706T3 (https=)
ES (1) ES2753381T3 (https=)
IL (1) IL240787B (https=)
MX (1) MX2015012818A (https=)
NZ (1) NZ713291A (https=)
WO (1) WO2014152776A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383117B (es) 2014-07-31 2025-03-13 Anji Pharmaceuticals Inc Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.
WO2017120568A1 (en) * 2016-01-08 2017-07-13 Lipimetix Development, Inc. Apoe mimetic peptide compositions
PL3416684T3 (pl) * 2016-02-17 2023-11-06 Regeneron Pharmaceuticals, Inc. Sposoby leczenia lub profilaktyki miażdżycy tętnic przez podawanie inhibitora angptl3
JP7541810B2 (ja) 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
WO2023018876A2 (en) * 2021-08-11 2023-02-16 The Regents Of The University Of California Barrier function preserving peptides for membranes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8557767B2 (en) * 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US20130005645A1 (en) * 2010-01-06 2013-01-03 Vitek Michael P Apoe peptide dimers and uses thereof
MX383117B (es) * 2014-07-31 2025-03-13 Anji Pharmaceuticals Inc Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.

Also Published As

Publication number Publication date
EP2996706A4 (en) 2017-01-18
BR112015022624A2 (pt) 2017-10-31
IL240787A0 (en) 2015-10-29
JP2019089834A (ja) 2019-06-13
AU2017203911B2 (en) 2019-03-07
AU2014239186A1 (en) 2015-10-08
JP6570511B2 (ja) 2019-09-04
EP2996706A1 (en) 2016-03-23
JP6772317B2 (ja) 2020-10-21
NZ713291A (en) 2017-04-28
AU2014239186B2 (en) 2017-04-20
EP2996706B1 (en) 2019-07-31
US20160002315A1 (en) 2016-01-07
WO2014152776A1 (en) 2014-09-25
MX2015012818A (es) 2016-05-12
JP2016515137A (ja) 2016-05-26
DK2996706T3 (da) 2019-10-21
CA2903869A1 (en) 2014-09-25
ES2753381T3 (es) 2020-04-08
AU2017203911A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
IL274355B (en) Aza-pyridone compounds and their uses
GB201317286D0 (en) Composition and Use
GB201323008D0 (en) Compounds and uses thereof
PT3058936T (pt) Composição peptídica e respetivos usos
GB201321693D0 (en) Composition and uses thereof
GB201305277D0 (en) Novel combination and use
EP2933176A4 (en) ROLLING BOARD ELEMENT AND SKATEBOARD COMPRISING THE SAME
PL3087092T3 (pl) Peptyd przeciwdrobnoustrojowy i jego zastosowania
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
IL243433A0 (en) Titanium bibory layers and their production
EP3007720A4 (en) COMPOSITION COMPRISING THE GC MACROPHAGE ACTIVATION FACTOR AND USES THEREOF
IL240787B (en) Mimetics of apoflavon and their uses
GB201307233D0 (en) Compounds and uses thereof
GB201309178D0 (en) Enzyme and uses thereof
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201307989D0 (en) Novel combinations and use
GB201320992D0 (en) Complex and uses thereof
GB201309180D0 (en) Compounds and Their Uses
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
GB201305297D0 (en) Novel agents and uses thereof
GB201301022D0 (en) Composition and uses thereof
GB201301393D0 (en) Kiddibidet and pottibidet
GB201323005D0 (en) Compounds and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed